Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Grant E. Barber"'
Autor:
Grant E. Barber, John Gubatan
Publikováno v:
Alimentary Pharmacology & Therapeutics. 57:569-570
Autor:
John Gubatan, Grant E. Barber, Ole Haagen Nielsen, Carsten Bogh Juhl, Cynthia Maxwell, Michael L. Eisenberg, Sarah E. Streett
Publikováno v:
Clinical Gastroenterology and Hepatology.
Studies evaluating reproductive outcomes among male patients with inflammatory bowel disease (IBD) are limited. We evaluated use of IBD medications and association with semen parameters, a proxy of male fertility, and adverse pregnancy outcomes (earl
Publikováno v:
Gastroenterology. 162:S-439
Publikováno v:
Gastroenterology. 162:S-100
Autor:
Sarah Lechner, Kian Keyashian, Monica Choe, Berkeley N. Limketkai, David Limsui, Steven Hendler, Grant E Barber
Publikováno v:
Digestive diseases and sciences. 67(4)
Crohn's disease (CD) and ulcerative colitis (UC) are complex, inflammatory bowel diseases (IBD) with debilitating complications. While severe IBD typically requires biologic agents, the optimal therapy for mild-moderate IBD is less clear. To assess t
Autor:
Berkeley N Limketkai, Philip N. Okafor, David Limsui, Grant E Barber, Matthew S. Chang, Steven Hendler
Publikováno v:
International journal of colorectal disease. 35(5)
Cytomegalovirus (CMV) infection may complicate ulcerative colitis (UC) or Crohn’s disease (CD) hospitalizations. Studies examining this relationship are often single-center examining short time periods. To quantify the prevalence of CMV and its imp
Autor:
Cynthia Maxwell, Grant E. Barber, Ole Haagen Nielsen, Sarah E. Streett, Cartsen Juhl, Michael Eisenberg, John Gubatan
Publikováno v:
American Journal of Gastroenterology. 116:S353-S353
Autor:
John J. Garber, Cosmas Giallourakis, Ramnik J. Xavier, Ashwin N. Ananthakrishnan, Grant E. Barber, Vijay Yajnik, Hamed Khalili
Publikováno v:
American Journal of Gastroenterology. 111:1816-1822
One-fifth of patients with Crohn's disease (CD) are primary non-responders to anti-tumor necrosis factor (anti-TNF) therapy, and an estimated 10-15% will fail therapy annually. Little is known about the genetics of response to anti-TNF therapy. The a
Publikováno v:
Infection Control & Hospital Epidemiology. 38:196-202
BACKGROUNDClostridium difficile infection (CDI) is the most common healthcare-associated infection and is associated with considerable morbidity. Recurrent CDI is a key contributing factor to this morbidity. Despite an estimated 83,000 recurrences an